Chimeric antigen receptor T-cell immunotherapy in breast cancer: development and challenges
Sara Toulouie, Gary L. Johanning, Yihui H. Shi · Journal of Cancer · 2021
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · review · 2021
Abstract
Chimeric antigen receptor (CAR) T-cell therapy is an innovative form of immunotherapy wherein autologous T-cells are genetically modified to express chimeric receptors encoding an antigen-specific single-chain variable fragment and costimulatory molecules.Moreover, CAR T-cell therapy can only work successfully in patients who have an intact immune system.Therefore, patients receiving cytotoxic chemotherapy will be immunosuppressed making CAR-T therapy less effective.In adoptive CD8+ T-cell therapy (ACT), numerous tumor-specific, engineered T-cells are sourced from patients, expanded in vitro, and infused back expressing tumor-specific antigen receptors.The most successful ACT, anti-CD19 chimeric antigen receptor T-cell therapy directed against B-cell lymphoma, has proved to be efficacious.However, current efforts to utilize this approach for solid tumors, like breast cancer, have shown only modest improvement.Nevertheless, the potential efficacy of CAR-T therapy is promising in an era of immunological advances.By appropriately manipulating CAR T-cells to combat the immunosuppressive forces of the tumor microenvironment, significant eradication of the solid tumor may occur.This review discusses CAR T-cell therapy and its specificity and safety in adoptive cell transfers in breast cancer.We will highlight novel discoveries in CAR T-cell immunotherapy and the formidable barriers including suppression of T-cell function and localization at tumor sites.
Open the resolved locator · 10.7150/jca.54095
Metadata licence: OpenAlex metadata (CC0)